Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn’s Disease in Italy

• DOI: 10.1007/s12325-024-02840-x
• Publication Date: 2024-04-15T08:01:56Z
• Authors: Melania Dovizio; Susanne Hartz; Carlotta Buzzoni; Isabel Redondo; Marijana Nedeljko...; Domenico Birra; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Alessandro Armuzzi
• Keywords: Healthcare cost; Inflammatory bowel disease; Real-world evidence; Therapeutics; Original Research

Real-world data are used to inform decision-makers and optimise therapeutic management for patients with ulcerative colitis (UC) Crohn's disease (CD). We analysed on the epidemiology (by using proxies of prevalence incidence), patient characteristics, treatment patterns associated healthcare direct costs UC CD in Italy. This retrospective observational study administrative databases from eight Local Health Units geographically distributed across Adult a hospitalisation and/or an exemption or were included. Study outcomes summarised descriptively, limited statistical tests performed. At baseline, 9255 adults 4747 Mean (standard deviation) age at inclusion was 54.0 (18.4)/48.6 (18.1) years, UC/CD. The estimated average incidence period 2013-2020 36.5 18.7 per 100,000, respectively. most frequently prescribed drug category UC/CD conventional [mesalazine topical corticosteroids (67.4%/61.1%), immunomodulators systemic (43.2%/47.7%)], followed by biologic treatments (2.1%/5.1%). mean annual total cost 7678 euro (€), €6925 CD. analysis, carried-out Italian clinical setting, may help therapy provide relevant practice decision-makers.